Format

Send to

Choose Destination
Breast Cancer Res. 2003;5(2):96-100. Epub 2003 Feb 3.

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.

Author information

1
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. carlos.arteaga@vanderbilt.edu

Abstract

Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metastatic breast tumors and prolongs patient survival. Single-agent Herceptin in patients with HER2-amplified breast tumors also induces a definite objective response and clinical benefit rates, and is well tolerated. These data suggest that Herceptin is an effective first-line single-agent therapy for a predictable cohort of metastatic breast cancers and can therefore be used as a platform for therapeutic discovery against tumors that overexpress HER2.

PMID:
12631388
PMCID:
PMC154152
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center